Association of Tourette Syndrome and Chronic Tic Disorder With Subsequent Risk of Alcohol- or Drug-Related Disorders, Criminal Convictions, and Death: A Population-Based Family Study.

Abstract

BACKGROUND:

It remains unclear if individuals with Tourette syndrome (TS) or chronic tic disorder (CTD) have an elevated risk of subsequent substance misuse.

METHODS:

In this population-based cohort study, we investigated the association between ICD diagnoses of TS/CTD and substance misuse outcomes, accounting for psychiatric comorbidity and familial factors. The cohort included all individuals living in Sweden at any time between January 1, 1973, and December 31, 2013. Substance misuse outcomes were defined as an ICD code of substance use-related disorder or cause of death, or as a substance use-related criminal conviction in the nationwide registers.

RESULTS:

The cohort included 14,277,199 individuals, of whom 7832 had a TS/CTD diagnosis (76.3% men). TS/CTD was associated with an increased risk of any subsequent substance misuse outcomes (adjusted hazard ratio [aHR], 3.11; 95% confidence interval [CI], 2.94-3.29), including alcohol-related disorder (aHR, 3.45; 95% CI, 3.19-3.72), drug-related disorder (aHR, 6.84; 95% CI, 6.32-7.40), substance-related criminal convictions (aHR, 2.56; 95% CI, 2.36-2.77), and substance-related death (aHR, 2.54; 95% CI, 1.83-3.52). Excluding psychiatric comorbidities had little effect on the magnitude of the associations, with the exception of attention-deficit/hyperactivity disorder, which attenuated the risk of any substance misuse outcomes (aHR, 2.00; 95% CI, 1.82-2.19). The risk of any substance misuse outcomes in individuals with TS/CTD was substantially attenuated but remained significant when compared with their unaffected siblings (aHR, 1.74; 95% CI, 1.53-1.97).

CONCLUSIONS:

TS/CTD were associated with various types of subsequent substance misuse outcomes, independently of psychiatric comorbidity and familial factors shared between siblings. Screening for drug and alcohol use should become part of the standard clinical routines, particularly in patients with comorbid attention-deficit/hyperactivity disorder.

• Authors: Suvi Virtanen, Anna Sidorchuk, Lorena Fernández de la Cruz, Gustaf Brander, Paul Lichtenstein, Antti Latvala, David Mataix-Cols
• Journal: Biological psychiatry (Biol Psychiatry) Vol. 89 Issue 4 Pg. 407-414 (Feb 15 2021) ISSN: 1873-2402 [Electronic] United States
• PMID: 33229038 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2020 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Chemical References

• Pharmaceutical Preparations

Topics

• Attention Deficit Disorder with Hyperactivity (epidemiology)
• Cohort Studies
• Comorbidity
• Criminals
• Female
• Humans
• Male
• Pharmaceutical Preparations
• Sweden (epidemiology)
• Tic Disorders (epidemiology)
• Tourette Syndrome (epidemiology)